<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01977508</url>
  </required_header>
  <id_info>
    <org_study_id>VAG-001</org_study_id>
    <nct_id>NCT01977508</nct_id>
  </id_info>
  <brief_title>The Vascutek Rapidax™ II Post Market Surveillance Registry</brief_title>
  <official_title>The Vascutek Rapidax™ II Post Market Surveillance Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascutek Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascutek Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre, prospective, observational post-market registry. To monitor and collect data on&#xD;
      the post-market clinical safety and performance of the Vascutek Rapidax II Vascular Access&#xD;
      Graft.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At least 10 patients who have been implanted with a Rapidax II Vascular Access Graft for&#xD;
      haemodialysis applications in patients with End Stage Renal Disease (ESRD), who are&#xD;
      undergoing or are scheduled to begin haemodialysis and require implant of a prosthetic graft.&#xD;
&#xD;
      Primary End Points:Safety and Performance&#xD;
&#xD;
        -  Secondary patency at 6 months post implant (Performance).(access survival until&#xD;
           abandonment). The interval from time of implant to abandonment or time of measurement of&#xD;
           patency, including intervention to re-establish the functionality of the thrombosed&#xD;
           access&#xD;
&#xD;
        -  Secondary patency at 12 months post implant (Performance.(access survival until&#xD;
           abandonment). The interval from time of implant to abandonment or time of measurement of&#xD;
           patency, including intervention to re-establish the functionality of the thrombosed&#xD;
           access&#xD;
&#xD;
        -  Freedom from device related Serious Adverse Events at 6 and 12 months (Safety)&#xD;
&#xD;
      Secondary End Points: Safety and performance&#xD;
&#xD;
        -  Primary patency at 6 months post implant (Performance. (intervention free access&#xD;
           survival). The interval from time of implant to any intervention designed to maintain or&#xD;
           re-establish patency or to access thrombosis&#xD;
&#xD;
        -  Primary patency at 12 months post implant (Performance).(intervention free access&#xD;
           survival). The interval from time of implant to any intervention designed to maintain or&#xD;
           re-establish patency or to access thrombosis&#xD;
&#xD;
        -  Assisted primary patency at 6 months (Performance. (thrombosis free access survival).&#xD;
           The interval from time of implant to intervention to maintain patency prior to the&#xD;
           occurrence of thrombosis&#xD;
&#xD;
        -  Freedom from device related Serious Adverse Events at 6 and 12 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Safety and Performance</measure>
    <time_frame>6 months</time_frame>
    <description>Secondary patency at 6 months post implant (Performance)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Performance</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary patency at 12 months post implant (Performance)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Performance</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from device related Serious Adverse Events at 6 and 12 months (Safety)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Performance</measure>
    <time_frame>6 months</time_frame>
    <description>Primary patency at 6 months post implant (Performance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Performance</measure>
    <time_frame>12 months</time_frame>
    <description>Primary patency at 12 months post implant (Performance)&#xD;
•</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Performance</measure>
    <time_frame>12 months</time_frame>
    <description>Assisted primary patency at 6 months (Performance)&#xD;
•</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Performance</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from device related Serious Adverse Events at 6 and 12 months</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>End Stage Kidney Disease</condition>
  <arm_group>
    <arm_group_label>haemodialysis vascular access using ePTFE grafts</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ePTFE vascular access grafts</intervention_name>
    <arm_group_label>haemodialysis vascular access using ePTFE grafts</arm_group_label>
    <other_name>RapidaxTM II Vascular access graft</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        At least 10 patients who have been implanted with a Rapidax II Vascular Access Graft for&#xD;
        haemodialysis applications in patients with End Stage Renal Disease (ESRD), who are&#xD;
        undergoing or are scheduled to begin haemodialysis and require implant of a prosthetic&#xD;
        graft.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is ≥ 18 and ≤ 90 years old&#xD;
&#xD;
          2. Subject has a life expectancy of at least 12 months&#xD;
&#xD;
          3. Subject is scheduled to undergo placement of a new straight or loop arm arteriovenous&#xD;
             haemodialysis access graft&#xD;
&#xD;
          4. The subject is willing and able to comply with the protocol and associated follow up&#xD;
             requirements&#xD;
&#xD;
          5. Subjects must have agreed for their data to be entered into the registry as per the&#xD;
             local hospital consent procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy or sensitivity to ePTFE&#xD;
&#xD;
          2. Subject unwilling or unable to comply with the protocol&#xD;
&#xD;
          3. Life expectancy of less than 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernd Lobenstein</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saale-Unstrut Klinikum Naumburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saale-Unstrut Klinikum Naumburg</name>
      <address>
        <city>Naumburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thüringen Kliniken Georguis</name>
      <address>
        <city>Saale</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medinos Klinik Sonneberg</name>
      <address>
        <city>Sonneberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>October 15, 2013</study_first_submitted>
  <study_first_submitted_qc>October 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2013</study_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vascular access grafts</keyword>
  <keyword>Haemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

